Phase 2 Irritable Bowel Syndrome Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Irritable Bowel Syndrome (IBS) according to a standard diagnostic framework called the Rome IV criteria
- People aged between 18 and 75 years
- People whose IBS symptoms are above a certain level of severity, as measured by a standard scoring tool (a score above 175 on the IBS-SSS scale)
- Women who could become pregnant must have been using an effective form of contraception (such as the pill, a hormonal implant, an IUD, or have had their tubes tied) for at least one month — unless they have gone through menopause (no periods for at least 12 months or confirmed by a blood test), or have had their uterus or fallopian tubes surgically removed
- People whose IBS treatments have not changed in the past month or more
- People who are members of a social security scheme (confirm with trial site)
- People who have read, understood, and signed the trial consent form
Who may not be able to join:
- People who have taken probiotics, food supplements containing glutamine, anti-inflammatory drugs, or antibiotics in the month before the study
- People with an allergy to fish or glutamine
- People with known serious kidney disease, known serious liver disease, or a known heart condition
- People with a history of certain other digestive conditions, such as coeliac disease or inflammatory bowel disease, or who have had abdominal surgery other than appendix or gallbladder removal
- Women who are pregnant, in labour, or currently breastfeeding
- People who are subject to certain legal restrictions on their personal freedoms or decision-making capacity (confirm with trial site)
- People who are currently taking part in another clinical trial, or who have taken part in one within the past four weeks
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chloé MELCHIOR, PUPH, University Hospital, Rouen
Phone: 00332 32 88 67 07
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Symptomatic efficacy of DIELEN® Protect supplementation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.